News & Updates

Show Multimedia Only

Baricitinib may improve hair regrowth in alopecia areata

02 May 2022 by

A once-daily dose of oral baricitinib may encourage hair regrowth in patients with severe alopecia areata, according to results of the phase III BRAVE-AA studies presented at AAD 2022.

02 May 2022

Dupilumab stops the itch, clears skin lesions in phase III trial

29 Apr 2022 by

The human monoclonal IgG4 antibody dupilumab effectively treats prurigo nodularis (PN), including itching and skin lesions, weeks after treatment in the phase III randomized, double-blind, LIBERTY-PN PRIME2 trial. Hopefully, this brings relief to patients suffering from uncontrolled PN.

29 Apr 2022

Cutaneous reactions after 1st COVID-19 vaccine dose no reason to forgo 2nd dose

27 Apr 2022 by

Skin reactions to the first COVID-19 vaccine in some individuals shouldn’t be a reason to leave out the second dose, or a scheduled booster if tolerable, according to an analysis presented at AAD 2022.

27 Apr 2022

Roflumilast cream reduces psoriasis severity

27 Apr 2022 by

Using a topical roflumilast cream to treat patients with chronic plaque psoriasis yields a significant improvement in disease severity, achieving a clear or almost clear IGA* status, based on a pooled analysis of the DERMIS-1** and DERMIS-2*** studies presented at AAD 2022.

27 Apr 2022

Asivatrep cream safe, effective for atopic dermatitis

26 Apr 2022

Asivatrep cream improves clinical signs and symptoms of atopic dermatitis without causing worrying adverse events, reports a recent study.

26 Apr 2022

New oral tyrosine kinase 2 inhibitor shows promise against moderate-to-severe plaque psoriasis

23 Apr 2022

PF-06826647, a novel tyrosine kinase 2 inhibitor in development, outperforms placebo at reducing disease severity in patient with moderate-to-severe plaque psoriasis, reveals a new trial.

23 Apr 2022

Ritlecitinib, brepocitinib show promise against scalp alopecia areata

22 Apr 2022

Ritlecitinib and brepocitinib lead to improvements in scalp alopecia areata and its associated biomarkers, reveals a recent substudy of a phase 2a trial.

22 Apr 2022

Topical therapy plus microneedling safe, effective in melasma management

03 Apr 2022

Use of microneedling appears to be a beneficial adjunct to topical medications in the treatment of melasma, suggests a recent study.

03 Apr 2022

More metastases, deaths seen in cutaneous squamous cell carcinomas with lymphovascular invasion

02 Apr 2022

The presence of lymphovascular invasion (LVI) in patients with cutaneous squamous cell carcinoma is associated with higher rates of metastasis and death at 5 years, reveals a recent study, noting that future staging systems must incorporate LVI.

02 Apr 2022

Abrocitinib effectively manages AD flares

21 Mar 2022 by

Rescue therapy using the Janus kinase 1 inhibitor abrocitinib combined with topical medicated therapy recaptured efficacy responses and had a favourable safety profile in individuals with moderate-to-severe atopic dermatitis (AD) who experienced flare during the maintenance period of the phase III randomized-withdrawal JADE REGIMEN trial.

21 Mar 2022